ライフサイエンスコーパス: malaise

1 /soreness, chills, arthralgia, anorexia, and malaise).

2 of the unconditioned stimulus for CTA (i.e., malaise).

3 intake and pica (i.e., behavioral measure of malaise).

4 fter exertion (referred to as postexertional malaise).

5 ebo group, and included headache, fever, and malaise).

6 ausea and vomiting, headache and significant malaise.

7 components of anxiety, stress, and visceral malaise.

8 avoidance of tastes associated with visceral malaise.

9 toxicity, nausea or vomiting, and fatigue or malaise.

10 nia, hyponatremia, hypokalemia, fatigue, and malaise.

11 lulike" illness associated with myalgias and malaise.

12 did not confirm that SEB challenge promotes malaise.

13 ng properties of LiCl or by a lesion-induced malaise.

14 ors, arthralgias, myalgias, headache, and/or malaise.

15 he expression of behaviors that alleviate GI malaise.

16 ratic heart rates and severe post-exertional malaise.

17 rgic terminals in the control of feeding and malaise.

18 CCK)-expressing VN neurons in motion-induced malaise.

19 t chronic fatigue and severe post-exertional malaise.

20 esting as severe fatigue and post-exertional malaise.

21 P as an agent to combat chemotherapy-induced malaise.

22 e effects were diarrhea, abdominal pain, and malaise.

23 ir the memory of cocaine reward with gastric malaise.

24 s required for avoidance induced by visceral malaise.

25 uding fever, abdominal cramps, tenesmus, and malaise.

26 s, after having experienced gastrointestinal malaise.

27 average meal size and independent of nausea/malaise.

28 body weight gain without causing CNS-related malaise.

29 l tastant and toxin-induced gastrointestinal malaise.

30 uffer from severe fatigue and postexertional malaise.

31 t presenting with complaints of headache and malaise.

32 also a harbinger of cellular and organismal malaise.

33 ssociated with grade I flu-like symptoms and malaise.

34 ic effect of NAc core GLP-1 is not caused by malaise.

35 he taste that was previously associated with malaise.

36 he taste that was previously associated with malaise.

37 7.94% in the 90- to180-day period), fatigue/malaise (12.82%; 5.87%), chest/throat pain (12.60%; 5.71

38 nes were well-tolerated, with myalgia (19%), malaise (14%), and local pain (10%) the most frequent ad

39 fatigue (29 [43%]), headache (26 [39%]), and malaise (15 [22%]).

40 a), fatigue (25 [47%]), headache (25 [47%]), malaise (18 [34%]), chills (12 [23%]), muscle ache (19 [

41 nd tenderness (27 [68%] of 40 participants), malaise (18 [45%] of 40 participants), headache (17 [43%

42 ary outcomes were fatigue and postexertional malaise 2 to 18 months after testing.

43 geal signs but less frequently complained of malaise; (2) had larger EM skin lesions despite similar

44 mphadenopathy (56%-86%), myalgias (31%-55%), malaise (23%-57%), and headache (25%-55%).

45 eveloped low-grade fever, chills, cough, and malaise 3 days prior to admission, and then progressive

46 (59.7%), headache (46.8%), fatigue (44.2%), malaise (39%), paresthesias (32.5%), peripheral facial p

47 ents treated with vorinostat were fatigue or malaise (51 [16%] patients in the vorinostat group vs 25

48 cific manifestations, including fever (96%), malaise (88%), myalgia (57%), cough (25%), and dizziness

49 mell (9.8% (7.7% to 11.8%)), post-exertional malaise (9.4% (6.1% to 12.7%)), fatigue (5.4% (1.2% to 9

50 becomes aversive if associated with gastric malaise, a form of learning known as conditioned taste a

51 ceptive cortex, during gastrointestinal (GI) malaise, a state akin to the emotion of disgust in human

52 past visual and motion memory, triggering a malaise accompanied by hypolocomotion, hypothermia, hypo

53 olism and deep vein thrombosis), fatigue and malaise, acute kidney disease, muscle pain, neurologic s

54 ed to this hospital because of confusion and malaise after resection of a papillary urothelial cancer

55 One patient had myalgias and malaise after the first infliximab infusion and flu-like

56 edical team member presenting with fever and malaise after travel to Haiti.

57 3 months) symptoms, including postexertional malaise, after SARS-CoV-2 infection were recruited in Sw

58 feverish, chills, muscle ache, headache, and malaise (all p<0.05).

59 xicity, including fever, chills, nausea, and malaise, although no patient had grade 3 or 4 toxicity.

60 escribed, including fatigue, post-exertional malaise and cognitive impairment.

61 ent developed new onset of nausea, vomiting, malaise and deep jaundice.

62 ttent, vague, and nonspecific, largely being malaise and easy fatiguability.

63 ic mechanism through which cisplatin-induced malaise and energy balance dysregulation are mediated.

64 She reported a general sense of malaise and experienced episodes of chills over the past

65 Systemic inflammation causes malaise and general feelings of discomfort.

66 n VRC 319 and 36 [80%] of 45 in VRC 320) and malaise and headache were the most frequent systemic sym

67 he presentation, in both instances, was with malaise and lethargy.

68 episodes, which in humans results in severe malaise and may lead to death.

69 very stage of learning (consumption, delayed malaise and memory retrieval).

70 Systemic reactions included mild to moderate malaise and myalgia.

71 -term emotional memories as assessed by odor-malaise and tone-shock associations.

72 V) developed signs of acute viral infection (malaise and weight loss) and had MCMV loads that were re

73 report unremitting fatigue, post-exertional malaise, and a variety of cognitive and autonomic dysfun

74 of symptoms such as fatigue, post-exertional malaise, and cognitive dysfunction that last for months

75 ms include fatigue, weakness, postexertional malaise, and cognitive dysfunction, with many other symp

76 patient presented with shortness of breath, malaise, and cough that had developed 3 days prior to ad

77 ted as an elevation in liver function tests, malaise, and edema.

78 Injection site reactions, fever, headache, malaise, and fatigue were common solicited AEs.

79 Constitutional symptoms (fever, malaise, and fatigue) and asymptomatic hyperbilirubinemi

80 ry embolism, chest pain, abnormal heartbeat, malaise, and fatigue, were replicated across both cohort

81 ost common systemic reactions were headache, malaise, and myalgia.

82 acne-like skin rash, leukopenia, fatigue and malaise, and nausea and vomiting.

83 rhythmia, diabetes, genitourinary disorders, malaise, and nonspecific chest pain.

84 condition marked by fatigue, post-exertional malaise, and other symptoms resembling myalgic encephalo

85 The home environment, parental malaise, and the child's own IQ may have a role in expla

86 nonspecific constitutional symptoms (fever, malaise, and weight loss) and elevated inflammatory mark

87 for the full expression of cisplatin-induced malaise, anorexia, and body weight loss.

88 hallmarks of infection have included fever, malaise, anorexia, gastrointestinal complaints, thromboc

89 entations with enlarged lymph nodes, fevers, malaise, anorexia, weight loss, hypoalbuminemia, and gas

90 tration, no effects of galantamine on nausea/malaise as measured by pica were noted.

91 arial rash, arthralgia, chills, headache and malaise associated with an autosomal-dominant inheritanc

92 (PBN) neurons prevents lethargy, anxiety and malaise associated with cancer.

93 s (CB) have been used to combat the visceral malaise associated with chronic disease, although the me

94 ls in the brainstem is a likely cause of the malaise associated with these disorders.

95 h as rats acquired and consolidated a taste-malaise association memory, and found specific differenc

96 ement of the Environment scores and parental malaise attenuated associations with the mother's IQ but

97 sing a small number of RBC units for general malaise attributed to anaemia, a practice that appears t

98 using small numbers of RBC units for general malaise attributed to anaemia, a practice which appears

99 R agonism blocks emesis and attenuates other malaise behaviors elicited by GLP-1R activation while ma

100 nd symptom scores on fatigue, postexertional malaise, breathlessness, cognitive difficulties, sleep p

101 a neuromodulator in the hindbrain to produce malaise by potentiating visceral afferent signaling at t

102 een associated with lithium chloride-induced malaise, c-Fos protein expression increased dramatically

103 erent families cause a syndrome of fever and malaise, 'capillary leak' with loss of plasma volume, an

104 eathing difficulties/breathlessness, fatigue/malaise, chest/throat pain, headache, abdominal symptoms

105 the amygdala with optogenetic stimulation of malaise-coding hindbrain neurons, we show that delayed m

106 bolites were identified in participants with malaise compared to those without.

107 We propose that visceral malaise contributes to the stressful and anxiogenic effe

108 the first dose and typically included fever, malaise, cough, dyspnea, and interstitial pneumonitis.

109 ection-site tenderness, arthralgia, fatigue, malaise) did not.

110 nfusion, there was resolution of fatigue and malaise, disappearance of fever, and regression of lymph

111 The degree of malaise-driven reactivation of individual neurons predic

112 Clinical symptomatology includes fatigue, malaise, dyspnea, defects in memory and concentration an

113 other neurological disorders (eg, fatigue or malaise, encephalitis or encephalopathy), following DENV

114 a novel flavor with subsequent sickness and malaise, even when these adverse effects occur minutes t

115 e symptoms (such as fever, chills, headache, malaise, fatigue, arthralgias, and myalgias) before rand

116 buting to PASC score included postexertional malaise, fatigue, brain fog, dizziness, gastrointestinal

117 e updated 2024 index included postexertional malaise, fatigue, brain fog, dizziness, palpitations, ch

118 cular disorders, gastrointestinal disorders, malaise, fatigue, musculoskeletal pain and anaemia.

119 s included anemia (33%), infection (24%) and malaise/fatigue (14%).

120 tural orthostatic tachycardia syndrome), and malaise/fatigue (including chronic fatigue syndrome).

121 3 or 4 treatment-related adverse events were malaise/fatigue and diarrhea, occurring in 17% and 7% of

122 es were anemia, leukopenia/granulocytopenia, malaise/fatigue, nausea/vomiting, alopecia, thrombocytop

123 her common but mild adverse effects included malaise/fatigue, peripheral edema, and hyperglycemia.

124 Diarrhea, nausea, malaise/fatigue, vomiting, and mucositis were the most c

125 for many symptoms such as sleep disorder and malaise/feebleness was also significantly improved after

126 n, visual loss, and constitutional symptoms (malaise, fever, weight loss, loss of appetite).

127 ffectiveness of cannabinoids in blocking the malaise generated by TNF-releasing disease processes by

128 loin pain, diarrhoea, and vomiting; one had malaise, headache, and chest pain; and one had severe ch

129 All patients had fever, malaise, headache, and lymphopenia; three had thrombocyt

130 fluconazole discontinued treatment owing to malaise, headache, and moderate dizziness (Common Termin

131 A gradual fever onset over 3-7 days with malaise, headache, and myalgia is typical.

132 Symptoms such as fever, nausea/vomiting, malaise, headache, and photophobia were significantly as

133 pain/tenderness, swelling, erythema, fatigue/malaise, headache, muscle pain, or fever was higher in i

134 ipients reported having injection-site pain, malaise, headache, or myalgia.

135 included gastrointestinal disorders, tremor, malaise, hyperhidrosis, and anorexia.

136 animals learn to associate novel taste with malaise (i.e., assign it negative valence).

137 ing fever in 23 (82%), headache in 14 (50%), malaise in 13 (46%), dizziness in nine (32%), myalgia in

138 ated distinct mechanisms for post-exertional malaise in CFS and START and STOPP phenotypes of GWI.

139 Marek's disease virus (MDV) causes a general malaise in chickens that is mostly characterized by the

140 Astronauts experienced a general post-flight malaise in motor function and motion perception, and a l

141 -induced pica (a proxy for nausea/behavioral malaise in nonvomiting laboratory rodents) and that CeA

142 entral GLP-1 system to mediate satiation and malaise in rats.

143 yalgia (in three), sore throat (in two), and malaise (in two), were also observed.

144 tested in rats with 2 measures sensitive to malaise, increased kaolin consumption (pica behavior) an

145 also independent of the incretin effects and malaise induced by GLP1 receptor (GLP1R) analogs, sugges

146 derstood and are investigated here using the malaise-inducing agent lithium chloride (LiCl).

147 charin) is paired to the administration of a malaise-inducing agent, such as intraperitoneal injectio

148 NPY's orexigenic and malaise-inducing properties were tested in rats with 2 m

149 s that exogenous NPY has both orexigenic and malaise-inducing properties.

150 by AgRP neuron ablation or gastrointestinal malaise inhibits feeding.

151 e general health questionnaire (GHQ) and the malaise inventory (divided into psychological and somati

152 or the psychological symptom subscale of the malaise inventory (regression coefficient -0.024, 95 per

153 was measured using the short version of the Malaise Inventory (scored 0-9).

154 lth Questionnaire, the Kessler 6, the 9-item Malaise Inventory, the Short Mood and Feelings Questionn

155 gh psychological and somatic symptoms on the malaise inventory.

156 eneral Health Questionnaire; NCDS and BCS70: Malaise Inventory; all: 2-item versions of Generalized A

157 ured using the Psychological subscale of the Malaise Inventory; frequency of physical activity, by qu

158 including fever (>/=38.5 degrees C), rigors, malaise, lethargy, flank pain, hematuria, suprapubic dis

159 ), nausea (50%), vomiting (34%), and fatigue/malaise/lethargy (24%).

160 e formation of a conditioned taste aversion (malaise-like behavior).

161 embolism, deep vein thrombosis, fatigue and malaise, liver disease, acute kidney injury, muscle pain

162 The acute presentation was with malaise, myalgia and weakness, nausea and vomiting, and

163 8.8% had other non-specific symptoms (fever, malaise, myalgia, arthralgia and disturbances of smell o

164 ia and constitutional symptoms consisting of malaise, myalgias, and anorexia were the dose-limiting t

165 re well tolerated, with injection site pain, malaise, myalgias, and headache being the most frequentl

166 His illness onset included malaise, myalgias, and low-grade fever.

167 nted with 6 days of sinus congestion, fever, malaise, myalgias, episcleritis, and a morbilliform rash

168 e (n = 10, 19%), headache (n = 10, 19%), and malaise (n = 6, 12%).

169 ent refusal (n=2); and arthralgia, rash, and malaise (n=1 each).

170 e for patients with cancer, often leading to malaise, neurologic dysfunction, or death.

171 %] of 171), headache (12 [7.0%] of 171), and malaise (nine [5.3%] of 171) in patients receiving ledip

172 g at a 10-fold lower dose was neither due to malaise nor motoric impairment.

173 higher odds of self-reported postexertional malaise (odds ratio, 2.04; 95% CI, 1.81-2.30), compared

174 ] with 2 mg, and seven [28%] with 6 mg), and malaise or fatigue (five [20%] with 0.67 mg, seven [28%]

175 y symptoms in the active vaccine groups were malaise or fatigue (five [50%] of ten in part A and 17 [

176 eadache in 31 (91%), chills in 25 (74%), and malaise or fatigue in 19 (56%) participants.

177 pertension, gastroesophageal reflux disease, malaise or fatigue, joint pain or myalgias, constipation

178 pertension, gastroesophageal reflux disease, malaise or fatigue, joint pain or myalgias, polyuria, we

179 nd tenderness in four participants (50%) and malaise or headache in three (38%) participants.

180 emented by additional samples of alates from Malaise or light traps.

181 ucleus accumbens-without inducing concurrent malaise or locomotor impairment.

182 ms following intravenous administration were malaise or myalgia in three (18%) participants and heada

183 ctions in meal size and is not due to nausea/malaise or prolonged suppression of locomotor activity.

184 These effects did not appear to be due to malaise or suppression of motor behavior because drug-tr

185 these data is that NPY produces some form of malaise or visceral illness.

186 de 3), and a composite of asthenia, fatigue, malaise, or lethargy (56% with any grade, 9% with grade

187 d stress but not palatable feeding, visceral malaise, or thermal pain.

188 Refractory giardiasis was associated with malaise (P = .007) and anorexia (P = .02), with previous

189 emale rats during the 24 h following a taste-malaise pairing.

190 The concept of postexertional malaise (PEM) with disabling symptom exacerbation after

191 ted with an elevated risk of post-exertional malaise (PEM), an acute exacerbation of symptoms and oth

192 Post-exertional malaise (PEM), defined as the exacerbation of the patien

193 lopment of PCS with fatigue, post-exertional malaise (PEM), orthostatic dysregulation, autonomous dys

194 79.4% of long COVID reported postexertional malaise (PEM).

195 g physical or mental efforts (postexertional malaise [PEM]), and either cognitive reports or physiolo

196 that pIC neurons play a critical role in GI malaise perception, and that the pIC influences the expr

197 (extremity paresthesia, arthralgia, myalgia, malaise, pruritus, headache, dizziness, metallic taste,

198 or loss in smell or taste, pain, and fatigue/malaise-related symptoms in adolescents.

199 Nausea, the unpleasant sensation of visceral malaise, remains a mysterious process.

200 ntinuities reveal how aspects of psychiatric malaise run deeper than our species' history.

201 Fatigue Assessment Scale) and postexertional malaise scores (DePaul Symptom Questionnaire) after indi

202 ding hindbrain neurons, we show that delayed malaise signals selectively reactivate flavour represent

203 liar, flavours with delayed gastrointestinal malaise signals to investigate how the brain represents

204 isms of nausea, particularly in understudied malaise states.

205 tioned stimulus [CS]) with the experience of malaise (such as that induced by LiCl; unconditioned sti

206 Post-exertional malaise suggests exercise alters central nervous system

207 in self-reported fatigue and postexertional malaise symptoms 2 to 18 months after mild infection.

208 reinforcer selective and not due to adverse malaise symptoms such as nausea.

209 n western Kenya using prokopack aspirations, malaise tent traps and ultraviolet (UV) light traps.

210 lood glucose levels nor did it induce nausea/malaise, thus revealing a selective role for these neuro

211 study shows that metabarcoding soil eDNA and Malaise trap bulk samples can provide valuable insights

212 rence of six arthropod groups represented in Malaise trap collections run by the BioSCAN project acro

213 le to that quantified locally with light and Malaise trap surveys, while vertebrate richness exceeded

214 Higher diversity levels were found in Malaise traps in summer whereas soil samples showed a di

215 h is applied to flying insects sampled by 39 Malaise traps placed in five biogeographic regions, eigh

216 pled over two weeks using 6-m Gressitt-style Malaise traps set at five heights (0 m-32 m-8 m interval

217 d species diversity between soil samples and Malaise traps, with only 11.8% species overlap.

218 s including profound fatigue, postexertional malaise, unrefreshing sleep, cognitive deficits, and ort

219 ugh, dyspnea, and chills with arthralgias or malaise usually from 4 to 8 hours later so that the temp

220 Pairing intraoral sucrose with malaise via injection of lithium chloride (LiCl) caused

221 ural effects of OEA may result from visceral malaise via the activation of TRPV1.

222 Fatigue or malaise was the most common systemic adverse event, repo

223 with GWI exhibit fatigue and post-exertional malaise, we employed an intermittent voluntary running e

224 n, he developed recurrent rashes with fever, malaise, weakness, hepatitis, weight loss, and renal fai

225 eiving placebo; constipation, dizziness, and malaise were more frequent with thalidomide.

226 Fever, cough, dyspnea and malaise were the symptoms most strongly associated with

227 cantly decreased food intake without causing malaise, whereas intracerebroventricular infusion of apo

228 ns and symptoms such as headache, fever, and malaise, which can progress to chronic airway inflammati

229 ry activity can cause physical and emotional malaise, which resembles depression, and the anhedonia a